In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ:NVCR) announced today 28 presentations on Tumor Treating Fields from externally led clinical research and analysis at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through November 19, in San Francisco. These 28 presentations add to the six clinical, 13 preclinical and 10 simulation study presentations on Tumor Treating Fields at SNO this year. A total of 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented. The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference and demonstrates what we believe to be a growing interest in Novocure’s cancer treatment among researchers and clinicians throughout the world.

The presentations focus on the use of Tumor Treating Fields for a variety of brain cancers, and highlight data and trial designs from ongoing investigator-sponsored clinical trials program for Tumor Treating Fields. The trials studied Tumor Treating Fields in patients with newly diagnosed and recurrent glioblastoma, and as a potential treatment for pediatric gliomas, low-grade gliomas, meningioma, and brain metastases from non-small cell lung cancer. The trials included patients from the U.S., Germany and Austria.

“We continue to see an increased external interest among the scientific community in exploring Tumor Treating Fields as a potential treatment option in a variety of solid tumor cancer types,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. “The external study of Tumor Treating Fields helps us to deepen our understanding of our treatment, which we believe will lead to better patient outcomes.”

Poster presentations

(QLIF-38) Tumor treating fields for the treatment of glioblastoma multiforme in daily praxis: experience from two hospitals in Germany. S. May. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(HOUT-06) TTFields for newly diagnosed Glioblastoma: Impact of consultation strategy. M. Proescholdt. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(NIMG-92) Volumetric response to TTFields in newly diagnosed GBM. C.F. Freyschlag. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(QLIF-32) Meeting the patients – meeting the needs: Platforms for patients using Optune® to exchange expertise. A.F. Keßler. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(PALL-01) One year with Optune® in Austria: First report on clinical outcomes. J. Kerschbaumer. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(QLIF-09) Longterm survival in glioblastoma patients after tumor treating fields (TTFields) therapy. A. Rulseh. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(NIMG-03) Quantitative MR measurements in glioblastoma patients: difference in mean diffusivity between Optune patients and patients with only standard treatment. J. Vymazal. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(QLIF-36) Role of nurses for the implementation of TTFields in daily clinical routine in glioblastoma treatment. M. Kilias. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(PDCT-07) Tumor treating fields for pediatric patients with high grade glioma: first case series in Germany. M. Wölfl. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(NIMG-67) Advanced perfusion and diffusion MR imaging in glioblastoma patients treated with tumor treating fields (TTFields) as first-line therapy. J.M. Connelly. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(QLIF-42) Incidence and characterization of dermatologic adverse events in patients treated with tumor treating fields and impact on overall survival. A. Sumrall. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(QLIF-16) Clinical and Social Challenges & Opportunities in Treating Glioblastoma with Tumor Treatment Fields, a Case Series. M. Nguyen. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(ACTR-49) The effect of tumor treating fields in WHO grade 2 and 3 gliomas. N. Blondin. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(RARE-16) Case report: delayed development of pseudoprogression in 2 glioblastoma patients treated with TTFields. S. Hurrell. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-43) Tumor treating field compliance and overall survival in patients with primary GBM. M. Pandey. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(RTHP-10) Impact of combination immunotherapy with tumor treating fields therapy in a glioma cohort. J. Schulte. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(SURG-04) Cranial bone defects in patients treated with TTFields: A case series. N. Thon. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(RTHP-26) Feasibility of a concomitant administration of alternating electric fields and radiotherapy – a planning study. C. Straube. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-54) Open-label phase 1 clinical trial testing Personalized and Targeted Intervention with skull remodelling surgery to MAximize Levels of TTFields intensity for higher treatment benefit - the OptimalTTF study. A.R. Korshoej. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-20) Finding a predictive marker for compliance to TTFields therapy – the comptune study. M.A. Proescholdt. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-40) Stereotactic radiosurgery and tumor treating fields in small cell lung cancer patients with limited brain metastases: a pilot and feasibility trial. C. Dulaney. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ATIM-04) A Multi-Institutional Pilot Study of Prophylactic Cranial Tumor-Treating Fields for Patients with Extensive-stage Small Cell Lung Cancer. N. Rana. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ATIM-07) Study of pembrolizumab, tumor treatment fields (Optune®) and temozolomide for older subjects with newly diagnosed glioblastoma. L. Donovan. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-29) A Phase 2 Study of TTFields and Pulsed Bevacizumab in Patients with Bevacizumab-refractory Recurrent Glioblastoma. D. Tran. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-62) A phase II study of tumor treating fields (TTFields) with temozolomide in patients with low-grade gliomas. T. Juarez. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-19) A Phase 2 study of Tumor Treating Fields and Bevacizumab in Recurrent or Progressive Meningioma. P. Kumthekar. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-44) Autopsy study on the effects of tumor treatment fields in recurrent glioblastoma: preliminary results and trial design. S. Hurrell. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(ACTR-73) A phase II study of tumor treating fields in combination with bevacizumab and temozolomide in patients with newly diagnosed, unresectable glioblastoma. A. Sumrall. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005609/en/

Source: Novocure